HULUWA(SH:605199) Zheng Quan Ri Bao·2025-10-30 23:05Core Viewpoint - The company, Hainan Huluwa Pharmaceutical Group Co., Ltd., is under risk warning due to a negative internal control audit report for the year 2024, leading to its stock being marked with "ST" starting April 30, 2025 [24][25][23]. Financial Data - The company has not conducted an audit for the third-quarter financial report [3][10]. - The financial data for the third quarter and the first nine months of 2025 are presented in RMB, but specific figures are not disclosed in the provided documents [11][12]. Internal Control and Compliance Measures - The company has established a special rectification team led by the chairman to address issues highlighted in the internal control audit report, focusing on areas such as research and development process management and financial management [25][26]. - Continuous internal self-inspections are being conducted to strengthen internal control management, including risk assessments of newly signed contracts [26][27]. - The company is enhancing its governance structure and compliance management, responding to regulatory requirements, and improving the quality of information disclosure [27][28]. Board Meeting and Management Changes - The company held its second temporary board meeting of 2025 on October 30, where it approved the third-quarter report and appointed Liu Quanguo as the new vice president [17][20][22]. - The meeting was attended by all seven board members, and the resolutions were passed unanimously [18][19]. Investor Communication - An investor performance briefing is scheduled for November 12, 2025, to discuss the third-quarter results and address investor inquiries [30][31]. - Investors can submit questions in advance through the designated channels before the briefing [32][34].